| Literature DB >> 27422761 |
Giorgio Bergamini1, Flurin Cathomas2, Sandra Auer3, Hannes Sigrist3, Erich Seifritz4, Michael Patterson5, Cecilia Gabriel6, Christopher R Pryce7.
Abstract
A major domain of depression is decreased motivation for reward. Translational automated tests can be applied in humans and animals to study operant reward behaviour, aetio-pathophysiology underlying deficits therein, and effects of antidepressant treatment. Three inter-related experiments were conducted to investigate depression-relevant effects of chronic psychosocial stress on operant behaviour in mice. (A) Non-manipulated mice were trained on a complex reversal learning (CRL) test with sucrose reinforcement; relative to vehicle (VEH), acute antidepressant agomelatine (AGO, 25mg/kg p.o.) increased reversals. (B) Mice underwent chronic social defeat (CSD) or control handling (CON) on days 1-15, and were administered AGO or VEH on days 10-22. In a progressive ratio schedule motivation test for sucrose on day 15, CSD mice made fewer responses; AGO tended to reverse this effect. In a CRL test on day 22, CSD mice completed fewer reversals; AGO tended to increase reversals in CSD mice associated with an adaptive increase in perseveration. (C) Mice with continuous operant access to water and saccharin solution in the home cage were exposed to CSD or CON; CSD mice made fewer responses for saccharin and water and drank less saccharin in the active period, and drank more water in the inactive period. In a separate CSD cohort, repeated AGO was without effect on these home cage operant and consummatory changes. Overall, this study demonstrates that psychosocial stress in mice leads to depression-relevant decreases in motivation and cognition in operant reward tests; partial reversal of these deficits by AGO provides evidence for predictive validity.Entities:
Keywords: Agomelatine; Animal model; Circadian rhythm; Decreased motivation; Depression; Operant
Mesh:
Substances:
Year: 2016 PMID: 27422761 DOI: 10.1016/j.euroneuro.2016.06.009
Source DB: PubMed Journal: Eur Neuropsychopharmacol ISSN: 0924-977X Impact factor: 4.600